{"id":203228,"name":"AMGEN USA INC.","slug":"amgen-usa-inc","state":"DC","country":"United States of America","description":"Biotechnology company.","totalSpending":1680000,"filings":29,"yearlySpending":[{"year":2019,"income":240000},{"year":2020,"income":240000},{"year":2021,"income":240000},{"year":2022,"income":240000},{"year":2023,"income":240000},{"year":2024,"income":240000},{"year":2025,"income":240000}],"issues":[{"code":"TAX","display":"Taxation/Internal Revenue Code"},{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"PHA","display":"Pharmacy"},{"code":"CPT","display":"Copyright/Patent/Trademark"},{"code":"TRD","display":"Trade (domestic/foreign)"},{"code":"BUD","display":"Budget/Appropriations"}],"firms":["MARSHALL & POPP, LLC"],"lobbyists":["MONICA POPP","HAZEN MARSHALL"],"govEntities":["Centers For Medicare and Medicaid Services (CMS)","Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","Natl Economic Council (NEC)","Office of the Vice President of the United States","White House Office","Office of Management & Budget (OMB)","SENATE","Food & Drug Administration (FDA)"],"sampleDescriptions":["Healthcare policy issues as they relate to the pharmaceutical industry including prescription drug value issues, FDA and biosimilars.","Healthcare policy issues as they relate to the pharmaceutical industry including prescription drug value issues, FDA and biosimilars.","Healthcare policy issues as they relate to the pharmaceutical industry including prescription drug value issues, FDA and biosimilars.","Healthcare policy issues as they relate to the pharmaceutical industry including prescription drug value issues, FDA and biosimilars.","Prescription drug value issues.\nBiosimilars.\n340B issues."]}